article thumbnail

A different approach: reimagining biology

Drug Discovery World

Three key members of the team – Dr Raquel Sanches-Kuiper, Vice President of Technology, Dr Matthew Hayes, Chief Technology Officer and John Edgell, Head of Cloud Engineering – explain how the company is doing this and what it means for the advancement of DNA synthesis in the lab. The next goal is to optimise the technology. “At

DNA 130
article thumbnail

How Targeted Cancer Drugs Disrupt the Cell Cycle

PLOS: DNA Science

A “DNA damage checkpoint” rests the cell cycle while special proteins repair damaged DNA. Here’s an article from 2002. The post How Targeted Cancer Drugs Disrupt the Cell Cycle appeared first on DNA Science. An “apoptosis checkpoint” turns on as mitosis begins.

Drugs 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Sanofi’s Board of Directors proposes the appointment of Carole Ferrand, Emile Voest and Antoine Yver as independent Directors

The Pharma Data

After ten years at Sony France as Chief Financial Officer (2000-2002), and then General Secretary, she was appointed Chief Financial Officer of Europacorp Group in 2011. She began her career in 1992 at PricewaterhouseCoopers where she worked as an auditor and then a financial advisor.

DNA 52
article thumbnail

What Took So Long: How Tech Has Finally Caught Up With Transcription Factors

LifeSciVC

These hair clip-like molecules clamp onto DNA, thereby turning many genes on and off. Darnell’s 2002 paper Transcription Factors as Targets for Cancer Therapy , in which he wrote: “A limited list of transcription factors are overactive in most human cancer cells, which makes them targets for the development of anticancer drugs.

article thumbnail

OBI Pharma Announces Presentations at ESMO Asia 2020 Virtual Annual Meeting for OBI-833, a Novel Anti-Globo H Targeted Therapeutic Cancer Vaccine

The Pharma Data

is a Taiwan biopharmaceutical company that was established in 2002. The company’s novel first-in-class AKR1C3 targeted therapy is OBI-3424 (small-molecule prodrug) that selectively releases a potent DNA alkylating agent in the presence of the aldo-keto reductase 1C3 (AKR1C3) enzyme. About OBI Pharma. OBI Pharma, Inc.,

Vaccine 52
article thumbnail

The evolution of cell therapy to address unmet medical needs

Drug Target Review

The other powerful benefit is that our cell lines can become any of the cell types of the human body – these cells have within their DNA the capability to become any of the more than 200 human cell types which you might want to manufacture. This provides some regulatory advantages, and of course, significant cost advantages.

article thumbnail

Defense-Forward Biosecurity

Codon

Allison Berke makes the case for real-time DNA sequencing and AI tools to detect pathogens before they spread widely. Reading DNA The first step in detecting a novel pathogen is recognizing it as an anomaly amidst a noisy background of other material. After copying the DNA to form a big pool, each piece is sequenced.

DNA 78